PFS Increased With Olaparib as Maintenance Therapy for BRCA+ Metastatic Pancreatic Cancer
June 2nd 2019The PARP inhibitor olaparib significantly improved progression-free survival in patients with germline BRCA-mutated metastatic pancreatic cancer compared to placebo when used as maintenance therapy in the phase III POLO trial, presented at the 2019 ASCO Annual Meeting.
Read More
Examining the Impact of Darolutamide on Pain and QoL in Patients With Nonmetastatic CRPC
June 2nd 2019Karim Fizazi, MD, PhD, professor and head of the GARD Inpatient Unit, at Institut Gustave Roussy, discusses the impact of darolutamide (ODM-201) on pain and quality of life in patients with nonmetastatic castration-resistant prostate cancer.
Watch
Patients With Stage III Melanoma Have Sustained Efficacy With Adjuvant Ipilimumab at 7 Years
June 2nd 2019Updated data from the phase III EORTC 18071 study showed that patients with surgically resected high-risk, stage III melanoma experienced a 25% reduction in the risk of recurrence or death with adjuvant ipilimumab compared with placebo.
Read More
Survival Is Improved in Metastatic Castration-Sensitive Prostate Cancer With Apalutamide
June 1st 2019Patients with metastatic castration-resistant prostate cancer who received apalutamide plus androgen deprivation therapy had a 33% reduced risk of death compared with patients taking androgen deprivation therapy alone in the phase III TITAN trial. Topline results from the trial were presented at the 2019 ASCO Annual Meeting and simultaneously published in the <em>New England Journal of Medicine.</em>
Read More
Updated Results from KEYNOTE-001 Show Favorable 5-Year OS Rates in Advanced NSCLC
June 1st 2019Overall survival from the KEYNOTE-001 trial in patients with advanced non–small cell lung cancer showed treatment with pembrolizumab monotherapy produced more favorable rates of response at 5 years when compared with historical, pre-immunotherapy standard-of-care regimens.
Read More
Improved OS Observed in HR+, HER2- Advanced Breast Cancer With Ribociclib Plus ET
June 1st 2019According to findings from the phase III MONALEESA-7 trial, peri and premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy demonstrated an estimated overall survival rate of 70.2% at 42 months compared with 46% for placebo and endocrine therapy.
Read More
Less AEs, Similar Efficacy Reported in Advanced G/GEJ Cancers With Frontline Pembrolizumab
June 1st 2019Patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer had non-inferior overall survival with frontline pembrolizumab compared with standard chemotherapy, according to results from the phase III KEYNOTE-062 trial.
Read More
Highlighting Key Trials in Kidney Cancer
June 1st 2019Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, at Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, at Harvard Medical School, highlights key trials in kidney cancer presented at the 2019 ASCO Annual Meeting.
Watch
ASCO to Recognize Leaders Transforming Cancer Care Around the World
May 31st 2019Ahead of the 2019 ASCO Annual Meeting, the American Society of Clinical Oncology announced leaders in the field of oncology who will be recognized during the upcoming annual meeting. The winners of ASCO’s Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards will be acknowledged for their work toward transforming cancer care around the world.
Read More
Oncology Experts Select Top Abstracts Ahead of 2019 ASCO Annual Meeting
May 29th 2019In an interview with <em>Targeted Oncology</em>, experts in gynecology, gastrointestinal, genitourinary, lung, and breast cancers spoke to the significance of the abstracts they are most looking forward to at the 2019 ASCO Annual Meeting.
Read More
Promising Responses Seen With Entrectinib in Pediatric Cancers, Including CNS Tumors
May 16th 2019One-hundred percent of pediatric patients with CNS and solid tumors harboring <em>NTRK1/2/3</em>, <em>ROS1</em>, or <em>ALK</em> gene fusions or mutations achieved objective responses with entrectinib, according to the phase I/Ib STARTRK-NG trial data presented in a press cast ahead of the 2019 ASCO Annual Meeting.
Read More
Dr. Posadas Discusses Darolutamide in Castration-Resistant Prostate Cancer
March 29th 2019Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor, Medicine, Cedars-Sinai Medical Center, discusses key takeaways from the ARAMIS trial of darolutamide in high-risk nonmetastatic castration-resistant prostate cancer.
Watch
Olaparib Combined With Neratinib May Be Novel Option for HER2+ Ovarian Cancer
March 20th 2019Olaparib combined with neratinib may be a novel treatment option for patients with HER2-positive, homologous recombination–proficient ovarian cancer tumors that are resistant to chemotherapy, preclinical findings presented during the 2019 SGO Annual Meeting showed.<br />
Read More
Promising Findings Seen With Neratinib in HER2-Mutant Cervical Cancer
March 19th 2019Neratinib demonstrated durable responses and disease control and a manageable safety profile in patients with metastatic <em>HER2</em>-mutant cervical cancer, according to results from the ongoing phase II SUMMIT basket trial.
Read More
Durable Responses Seen With Pembrolizumab/Bevacizumab Regimen in Ovarian Cancer
March 18th 2019Women with recurrent ovarian cancer treated with the combination of pembrolizumab, bevacizumab, and metronomic cyclophosphamide had a 95% disease control rate and a 40% overall response rate, according to findings from an open-label phase II study presented during the 2019 SGO Annual Meeting.
Read More
Lenvatinib Plus Paclitaxel Shows Activity in Ovarian, Endometrial Cancers
March 18th 2019Activity was seen with lenvatinib plus a weekly dose of paclitaxel in patients with recurrent endometrial and platinum-resistant epitherlial ovarian cancer, according to a presentation at the 50th SGO Annual Meeting. The combination resulted in a 65% overall response rate in a phase I trial.
Read More
Evaluating the Benefits of Lenvatinib and Paclitaxel in Recurrent Gynecologic Cancers
March 18th 2019Floor J. Backes, MD, discusses the results from a phase I trial investigating the combination of lenvatinib (Lenvima) and paclitaxel in patients with recurrent ovarian, fallopian tube, or peritoneal cancers.
Watch
TEAEs Decreased With Individualized Dose of Niraparib in High-Risk Ovarian Cancer
March 17th 2019Patients with high-risk ovarian cancer being treated with niraparib experienced a decrease in adverse events when treated with a 200- or 300-mg individualized starting dose based on bodyweight and platelet count compared with patients who received a fixed starting dose of 300 mg, according to data from a recent analysis of the ongoing ENGOT-OV26/PRIMA study.
Read More
Repeat PARP Use May Benefit Women With Recurrent Ovarian Cancer
March 17th 2019Repeated use of PARP inhibitors may be a beneficial treatment strategy in the future for women with recurrent epithelial ovarian cancer, according to the results of a retrospective, multi-institutional study presented at the 2019 SGO Annual Meeting. The findings suggested that prior exposure to PARP inhibition may not lead to resistance, which could lead to increased use of repeat PARP treatment going forward.
Read More
PFS Increased With Niraparib Without Symptoms or Toxicity in Ovarian Cancer
March 17th 2019Treatment with maintenance niraparib led to extended progression-free survival time in patients with recurrent ovarian cancer without the patients experiencing symptoms or toxicity compared with placebo, according to results of an analysis from the phase III ENGOT-OV16/NOVA trial. In patients with germline <em>BRCA</em>-mutated disease, the benefit was increased 4-fold and in patients non–germline <em>BRCA</em>-mutated ovarian cancer the benefit was increased 2-fold.
Read More
Encouraging Activity Seen With Pembrolizumab in Non-Clear Cell RCC
February 18th 2019First-line treatment with single-agent pembrolizumab induced a 24.8% overall response rate in patients with non-clear cell renal cell carcinoma, according to findings from cohort B of the phase II KEYNOTE-427 trial that were presented during the 2019 Genitourinary Cancers Symposium.<br />
Read More
Pembrolizumab/Cabozantinib Combo Active in Metastatic RCC
February 17th 2019According to phase I findings from a dose-escalation cohort presented during the 2019 Genitourinary Cancers Symposium, the combination of pembrolizumab and cabozantinib demonstrated antitumor activity in patients with previously treated metastatic renal cell carcinoma and is tolerated at their approved doses for this indication.
Read More
Patients With mCRPC May Have Reduced Skeletal Events With Layered Radium-223/Abiraterone
February 16th 2019Retrospective findings reported during the 2019 Genitourinary Cancers Symposium showed patients with metastatic castration-resistant prostate cancer who received radium-223 dichloride with abiraterone acetate in a layered fashion experienced a lower rate of symptomatic skeletal events compared with those who received the treatments concurrently.
Read More
Enzalutamide Leads to Extended Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer
February 16th 2019Adding enzalutamide (Xtandi) to androgen deprivation therapy led to prolonged radiographic progression-free survival compared with ADT alone in men with metastatic hormone-sensitive prostate cancer, investigators reported during the 2019 Genitourinary Cancers Symposium.
Read More
Metastasis-Free Survival Improved With Darolutamide in Nonmetastatic CRPC
February 16th 2019According to data from the phase III ARAMIS trial presented during the 2019 Genitourinary Cancers Symposium, darolutamide added to androgen deprivation therapy significantly improved metastasis-free survival compared with placebo plus ADT in patients with nonmetastatic castration-resistant prostate cancer.
Read More
Updated Findings Show Sustained OS Benefit With Nivolumab/Ipilimumab Combo in Frontline RCC
February 14th 2019In updated 30-month follow-up data from the phase III CheckMate-214 trial, nivolumab combined with low-dose ipilimumab sustained strong responses and a survival benefit as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma.
Read More